ICICI Securities research report on Nestle India
Our assertion / hypothesis: Nestlé’s infant nutrition business (~30% of revenues and ~40% of profits) will likely face growth headwinds in CY2021 due to consumers (now) delaying plans of having infants / babies due to fear of visiting hospitals. Given the premium pricing of infant nutrition products, the consuming households are mostly the upper-middle class / middle class, in our view. We have drawn conclusions from (1) our primary research with pharmaceutical companies and (2) secondary sales data (market research) from AIOCD-AWACS (MUST see charts 1-3).
Outlook
Though we are believers in Nestlé’s long-term story, our current neutral stance is intact (given that only a part of its portfolio (Maggi and (somewhat) Coffee) would benefit from increased in-home consumption). HOLD rating retained.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.